Berberine induces autophagy in glioblastoma by targeting the AMPK/mTOR/ULK1-pathway

Area of Science:

• Oncology
• Molecular Biology
• Metabolic Pathways

Background:

• Glioblastoma multiforme (GBM) necessitates novel therapeutic strategies.
• Berberine (BBR), a natural alkaloid, exhibits anti-tumor properties.
• Mechanisms of BBR-induced cancer cell death require elucidation.

Purpose of the Study:

• To investigate the effects of BBR on GBM cell metabolism.
• To elucidate the molecular mechanisms underlying BBR's anti-cancer activity.
• To evaluate the therapeutic potential of BBR in GBM.

Main Methods:

• Analysis of autophagy flux and glycolytic capacity in GBM cells treated with BBR.
• Investigation of the AMPK/mTOR/ULK1 signaling pathway.
• Assessment of BBR's efficacy in reducing tumor growth in vivo.

Main Results:

• BBR treatment leads to high autophagy flux and impaired glycolytic capacity in GBM cells.
• BBR inhibits the AMPK/mTOR/ULK1 pathway.
• BBR reduces GBM cell invasiveness, proliferation, and induces apoptosis.
• BBR significantly inhibits tumor growth in vivo.

Conclusions:

• BBR profoundly alters GBM cell metabolism, promoting autophagy and inhibiting glycolysis.
• Inhibition of the AMPK/mTOR/ULK1 pathway is a key molecular event.
• BBR demonstrates significant anti-tumor effects in vitro and in vivo.
• Autophagy-modulating plant alkaloids like BBR hold clinical potential for GBM therapy.